Literature DB >> 16055182

A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages.

Jennifer E I Wright1, Sebastien A Gittens, Geeti Bansal, Pavel I Kitov, Dennis Sindrey, Cezary Kucharski, Hasan Uludağ.   

Abstract

Chemical conjugation of bisphosphonates (BPs) to therapeutic proteins is an effective means to impart mineral affinity to proteins. Such conjugates can be implanted with mineral-based matrices to control the local delivery kinetics of the proteins. BPs linked to proteins with reversible (i.e., cleavable) linkages are desirable over conjugates with stable linkages to release the protein in free form. This study conducted a direct comparison of mineral affinity of BP-protein conjugates linked together with cleavable disulfide and non-cleavable thioether linkages. Bovine serum albumin (BSA) was used as a model protein and the desired conjugates were created with N-succinimidyl-3-(2-pyridyldithio)propionate (disulfide) and succinimidyl-4-(N-maleimido-methyl)cyclohexane-1-carboxylate (thioether) linkers. The disulfide-linked conjugates were cleaved in the presence of a major thiol constituent of serum, cysteine. The imparted mineral affinity, as assessed by hydroxyapatite binding in vitro, was lost upon the cleavage of the disulfide-linked aminoBP. The presence of the serum did not accelerate the cleavage of disulfide-linked conjugates. The aminoBP-BSA conjugates formed with disulfide and thioether linkages were subcutaneously implanted in rats with two different mineral-based matrices to assess protein loss from the matrices. All conjugates exhibited a higher retention in mineral matrices as compared to unmodified BSA. However, no significant differences in in situ pharmacokinetics of the disulfide- and thioether-linked conjugates were observed. We conclude that disulfide-linked BP conjugates were readily cleavable by the amino acid cysteine in vitro, but in vivo cleavage of the disulfide-linked conjugates was not evident when the proteins were implanted adsorbed to mineral-based matrices. BP-protein conjugates with faster-cleaving tethers might be required to significantly influence the release of the BP conjugates from the mineral matrices.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055182     DOI: 10.1016/j.biomaterials.2005.06.012

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

2.  Characterization of synthesized NANO-encapsulated drug for bone loss on hind limb suspension rat model by NMR and micro-CT.

Authors:  Qingwen Ni; Hong Dixon; Gloria Gutierrez; Long Bi; Yi-Xian Qin
Journal:  Adv Biosci Bioeng (N Y)       Date:  2014-06-14

3.  Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity.

Authors:  Xiang Yi; Dongfen Yuan; Susan A Farr; William A Banks; Chi-Duen Poon; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-02       Impact factor: 9.776

4.  Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction.

Authors:  Joseph Vanderburgh; Jordan L Hill; Mukesh K Gupta; Kristin A Kwakwa; Sean K Wang; Kathleen Moyer; Sean K Bedingfield; Alyssa R Merkel; Richard d'Arcy; Scott A Guelcher; Julie A Rhoades; Craig L Duvall
Journal:  ACS Nano       Date:  2020-01-08       Impact factor: 15.881

5.  Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties.

Authors:  Rosario Pignatello; Maria Grazia Sarpietro; Francesco Castelli
Journal:  J Funct Biomater       Date:  2012-01-19

Review 6.  New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors.

Authors:  Yu Zhong; Su Li
Journal:  Drug Des Devel Ther       Date:  2021-12-10       Impact factor: 4.162

Review 7.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.